AstraZeneca PLC (AZN) FinancialsAZNFinancialAstraZeneca PLC

AstraZeneca PLC (AZN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Farxiga, accounting for 15.2% of total sales, equivalent to $2.19B. Other significant revenue streams include Tagrisso and Imfinzi. Understanding this composition is critical for investors evaluating how AZN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, AstraZeneca PLC maintains a gross margin of 81.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.48%, while the net margin is 16.30%. These profitability ratios, combined with a Return on Equity (ROE) of 21.99%, provide a clear picture of how effectively AZN converts its operational activities into shareholder value.

In the context of the broader market, AZN competes directly with industry leaders such as PFE and NVS. With a market capitalization of $242.64B, it holds a significant position in the sector. When comparing efficiency, AZN's gross margin of 81.25% stands against PFE's 67.81% and NVS's 75.39%. Such benchmarking helps identify whether AstraZeneca PLC is trading at a premium or discount relative to its financial performance.

AstraZeneca has shown robust financial performance with total revenue for Q2 2026 at $15.38 billion and a net income of $2.51 billion, resulting in a net margin of 16.3%. The gross margin remains strong at 81.25%, indicating efficient cost management.